Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPB-1523 for MRI in HCC
NCT03407495Phase 2Completed
- Sponsor
- MegaPro Biomedical
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MPB-1523 in hepatocellular carcinoma (HCC), sponsored by MegaPro Biomedical. Primary endpoint: Sensitivity and specificity of IOP-enhanced MRI. Started Nov 2018; status: completed.
02
Drugs
MPB-1523
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03407495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407495.